Repligen Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Repligen Corporation - overview
Established
1981
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 1981, Repligen Corporation, a. k. a. Repligen operates a bioprocessing-focused life sciences company that focuses on developing and manufacturing advanced bioprocessing technologies, specializing in biopharmaceutical production solutions.
In July 2024, Repligen Corporation agreed to acquire Tantti from Taiwania Capital, Mega International Commercial Bank, Harbinger, Taian Biotechnology, Original Investment, National Development Fund of the Executive Yuan, and SinoPac Asset Management International. As of September 2024, the company is publicly trading on Nasdaq under the ticker symbol RGEN. Repligen specializes in bioprocessing solutions, focusing primarily on advanced technologies that enhance chromatography and filtration processes. The company’s core product offerings include the KrosFlo® TFF systems, designed for tangential flow filtration, and XCell® ATF Technology, which is utilized for upstream intensification in biomanufacturing.
These systems enable the efficient production of various biotherapeutics, including plasmid DNA, viral vectors, and mRNA, addressing challenges in recovery rates and operational efficiency. Repligen’s products are engineered to comply with current Good Manufacturing Practices (cGMP), catering to pharmaceutical and biotechnology companies across North America, Europe, and Asia. The company's clientele comprises leading biopharmaceutical firms and research institutions. Repligen's revenue model is primarily based on direct sales to its clients, which include large-scale biopharmaceutical manufacturers and research laboratories.
The company generates income through the sale of proprietary systems such as the KrosFlo® TFF systems and XCell® ATF Technology, along with consumables and software solutions that support these systems. Repligen plans to enhance its product line with upcoming launches of new technologies designed to improve bioprocessing efficiency, projected for release in 2024. The company aims to expand its market reach specifically in Asia and Europe by 2025, increasing its footprint in these regions.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Medical Devices & Equipment
Website
www.repligen.com
Verticals
E-commerce, Manufacturing
Total Amount Raised
Subscriber access only
Repligen Corporation - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Tantti | - | ||||||||
| Trade Sale | Completed | Metenova AB | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.